Summary
MediWound Q1 Earnings Call Highlights
MediWound NASDAQ: MDWD reported a wider first-quarter loss and lower revenue compared with the prior-year period, while management reaffirmed its 2026 revenue outlook and said it continued to advance its EscharEx and NexoBrid programs.
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
MediWound (MDWD) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.07 per share a year ago.
MediWound Ltd. (MDWD) Q4 2025 Earnings Call Transcript
MediWound Ltd. (MDWD) Q4 2025 Earnings Call Transcript
MediWound Ltd. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 175,479 | $2.83M | $2.47M | -$354,467.9 | -12.54% |
| YA Yinka Akinsola Blue Trust Inc. | 940 | $16,976.4 | $13,254 | -$3,722.4 | -21.93% |
| JC Joseph Castro Nuveen LLC | 10,799 | $167,600 | $152,157.91 | -$15,442.09 | -9.21% |
 Alexandra Stickelman Root Financial Partners, LLC | 3 | $48 | $42.27 | -$5.73 | -11.94% |
| VT Vincent Tortorella Point72 (DIFC) Ltd | 527 | $9,497 | $7,425.43 | -$2,071.57 | -21.81% |
MediWound Ltd. (MDWD) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has MediWound Ltd. ever had a stock split?
MediWound Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Ofer Gonen CEO | NASDAQ (NMS) Exchange | M68830104 CUSIP |
| IL Country | 111 Employees | - Last Dividend | 20 Dec 2022 Last Split | 20 Mar 2014 IPO Date |
Overview
MediWound Ltd. operates as a biopharmaceutical entity dedicated to pioneering the development, manufacturing, and global commercialization of innovative bio-therapeutic and non-surgical solutions aimed at tissue repair and regeneration. With its foundations laid in 2000 and a base of operations in Yavne, Israel, MediWound has extended its outreach and distribution not only across the United States and Europe but also internationally. The company's milestones in research and development in bio-pharmaceutics have established it as a significant player in providing advanced medical solutions for tissue regeneration and repair.
Products and Services
- NexoBrid
NexoBrid represents one of MediWound's flagship biopharmaceutical offerings. It is specifically formulated for the enzymatic removal of eschar, a type of dead or damaged tissue resultant from deep partial- and full-thickness thermal burns. This product has found widespread application and is actively marketed to burn centers and hospital burn units. Its non-surgical approach facilitates the debridement process, making it a critical tool in burn care and management.
- EscharEx
EscharEx is another innovative solution by MediWound, currently in advanced stages of research, having completed Phase II clinical trials. This product is designed for the debridement of chronic wounds and other hard-to-heal injuries, providing a non-surgical alternative for wound care specialists. The design and utility of EscharEx underscore MediWound's commitment to extending its tissue repair and regeneration technologies to encompass not only acute but also chronic wound care.
- MW005
MW005 is in the phase I/II clinical trial stage and is being developed as a treatment for low-risk basal cell carcinoma, a common form of skin cancer. MediWound's foray into oncological care with MW005 emphasizes its versatile approach to leveraging biotechnology in developing treatments for a broad range of tissue damage, including malignancies.
